{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:14:54Z","timestamp":1761581694976},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00262-018-2167-3","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T05:25:25Z","timestamp":1525411525000},"page":"1105-1111","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pushing the limits of immune-related response: a case of \u201cextreme pseudoprogression\u201d"],"prefix":"10.1007","volume":"67","author":[{"given":"Alvin S.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Liang","family":"Thian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeevesh","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Nang","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Tsu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"issue":"11","key":"2167_CR1","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00262-016-1898-2","volume":"65","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, Mozillo N (2016) Complete response to nivolumab monotherapy in a treatment-na\u00efve, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunol Immunother 65(11):1395\u20131400","journal-title":"Cancer Immunol Immunother"},{"key":"2167_CR2","doi-asserted-by":"publisher","first-page":"e28780","DOI":"10.4161\/onci.28780","volume":"3","author":"AM Grimaldi","year":"2014","unstructured":"Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M et al (2014) Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 3:e28780","journal-title":"Oncoimmunology"},{"issue":"1","key":"2167_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","volume":"66","author":"TK Owonikoko","year":"2017","unstructured":"Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, Nautiyal V, Chatwal MS, Book WM, Sahu A et al (2017) Cardiac allograft rejection as a complication of PD\u20111 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother 66(1):45\u201350","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2167_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64(6):765\u2013767","journal-title":"Cancer Immunol Immunother"},{"issue":"31","key":"2167_CR5","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541\u20133543","journal-title":"J Clin Oncol"},{"issue":"15","key":"2167_CR6","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R (2017) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23(15):4242\u20134250","journal-title":"Clin Cancer Res"},{"key":"2167_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-016-0134-0","volume":"4","author":"M Nishino","year":"2016","unstructured":"Nishino M (2016) Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a \u201ccommon language\u201d for the new arena of cancer treatment. J Immunother Cancer 4:30","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2167_CR8","doi-asserted-by":"publisher","first-page":"e143-e152","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143-e152","journal-title":"Lancet Oncol"},{"issue":"13","key":"2167_CR9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","volume":"34","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 34(13):1510\u20131517","journal-title":"J Clin Oncol"},{"issue":"23","key":"2167_CR10","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412\u20137420","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2167_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JM Ebos","year":"2009","unstructured":"Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232\u2013239","journal-title":"Cancer Cell"},{"issue":"1","key":"2167_CR12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.eururo.2014.10.034","volume":"68","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Massari F, Albiges L, Loriot Y, Massard C, Fizazi K, Escudier B (2015) Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol 68(1):154\u2013160","journal-title":"Eur Urol"},{"issue":"9","key":"2167_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","volume":"2","author":"S George","year":"2016","unstructured":"George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI (2016) Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol 2(9):1179\u20131186","journal-title":"JAMA Oncol"},{"issue":"3","key":"2167_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG et al (2017) Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol 72(3):368\u2013376","journal-title":"Eur Urol"},{"issue":"11","key":"2167_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","volume":"3","author":"GV Long","year":"2017","unstructured":"Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, M\u00e1rquez-Rodas I, McNeil C et al (2017) Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol 3(11):1511\u20131519","journal-title":"JAMA Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2167-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:04:38Z","timestamp":1556910278000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2167-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2167"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2167-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"11 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}